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I. INTRODUCTION
In Arthrex, Inc. v. Smith & Nephew, Inc., Arthrex challenged the
appointment of administrative patent judges who preside over inter partes
review and other post grant proceedings before the Patent Trial & Appeal
Board.1 Arthrex, as well as other dissatisfied patent owners who made
similar challenges, claimed that adverse decisions were constitutionally
improper and should be vacated, or at least remanded for further
proceedings, because the appointment of the administrative law judges who
oversaw the proceeding were constitutionally improper. The Supreme Court
made clear what should be done in the lead case, U.S. v. Arthrex, but similar
challenges remained pending in over a hundred others. This Article
examines how the Federal Circuit, the USPTO, and the parties dealt with the
Arthrex decision, and provides some perspectives on how Arthrex has
influenced PTAB trials.
II. BACKGROUND
The Leahy-Smith America Invents Act of 2011 (AIA) set forth a new
administrative litigation regime for challenging the patentability of an
existing patent.2 The AIA provides a means for parties to file petitions that
challenge the patentability of existing patents through proceedings like inter
partes review (IPR) and post-grant review (PGR). Congress also created the
Patent and Trial Appeal Board (PTAB), organized within the USPTO, to
oversee and administer proceedings under the AIA.3
Most PTAB proceedings are handled by three-member panels of
administrative patent judges (APJs), who are USPTO employees. APJs
generally preside over the proceedings, consider and rule on motions,
conduct an oral hearing, and prepare the PTAB’s final written decisions
concerning the patentability challenges presented in the petitions. Final
written decisions for the trials are final and binding on the parties, but may
be appealed to the United States Court of Appeals for the Federal Circuit.4
The key issue raised in United States v. Arthrex, Inc., 141 S.Ct. 1970,
1979-80 (2021), was how these APJs are hired and supervised. Congress
provided that APJs would be appointed as inferior officers by the Secretary
of Commerce as a head of a department.5 Inferior officers are positions that
need not be made by the President, nor confirmed by the Senate, unlike
principal officers such as the USPTO Director. But neither the Secretary of
1. Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019).
2. 35 U.S.C. §§ 6, §311(a).
3. About PTAB, USPTO, https://www.uspto.gov/patents/ptab/about-ptab [https://perma.cc/4VG6C9EJ] (last visited September 9, 2021).
4. United States v. Arthrex, Inc., 141 S.Ct. 1970, 1977 (2021).
5. Id. at 1980.
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Commerce nor the USPTO Director had the power to review the APJs’ final
written decisions or remove them at will.6
These limitations created a problem. Under the Constitution, an inferior
officer must either be removable at will by a head of a department, or have a
principal officer who reviews their decisions.7 But because APJs’ final
written decisions were not subject to USPTO Director review, and because
APJs could not be removed at will, they were, effectively, acting as principal
officers without ever having been appointed or approved as such, and
without principal officer management and oversight.
This brings us to the Federal Circuit’s October 31, 2019, Arthrex
decision. By late 2019, APJs had presided over thousands of trials, issuing
hundreds of final written decisions. But in Arthrex, a patent owner appealed
the PTAB’s final written decision invalidating its patent to the Federal
Circuit, and complained, in part, that APJs’ appointments violated the
Appointments Clause of the United States Constitution. 8 The Federal Circuit
agreed that the AIA “as currently constructed makes the APJs principal
officers.”9 To cure this problem, the Federal Circuit severed the part of Title
35 (the Patent Act) that limited APJ removal, making them removable at will
and, ostensibly, inferior officers.10 Seeing the problem as resolved, the
Federal Circuit decided to remand the case to the PTAB to be assigned to a
new panel of APJs.11 All parties to the appeal, including the government,
filed petitions for panel and en banc rehearing of the decision, all of which
the Federal Circuit denied. The parties and the government then took their
cases to the Supreme Court, which granted the petitions for certiorari.
On June 21, 2021, the Supreme Court vacated the Federal Circuit
decision. The Court agreed with the Federal Circuit that APJs were acting
as principal officers in IPR and other PTAB proceedings due to their
unreviewable authority to decide patentability.12 But while the Supreme
Court agreed there was a constitutional problem, it disagreed with the
Federal Circuit on how to fix it. The Supreme Court determined that the
proper remedy for the constitutional deficiency is for APJ decisions to be
reviewable by the Director of the United States Patent and Trademark Office.
While the director is not required to review every decision by an APJ, the
Court determined that the director must have the discretion to review any
and all decisions to satisfy the Appointments Clause.13 The Court remanded
to the director to determine whether discretionary review was appropriate.
6. Id.
7. Id. at 1974-80.
8. Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019).
9. Id. at 1325.
10. Id.
11. Id. at 1340.
12. Arthrex, Inc., 141 S. Ct., at 1977 (2021).
13. Id. at 1988. Note, however, that Drew Hirshfeld is only acting director of the USPTO. There
is not currently a director that has been confirmed by the Senate. Drew Hirshfeld, U.S. DEP. COMM.,
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The year-and-a-half gap between the original Federal Circuit decision
and the Supreme Court opinion left over 100 appeals from the PTAB to the
Federal Circuit without a clear path forward. Like the patent owner in
Arthrex, many patent owners asserted their own challenges to the APJs’
appointments. This Article discusses how the Federal Circuit, the USPTO,
and the parties have handled the fallout from the Arthrex decision, and how
Arthrex will impact practice before the PTAB in the years to come.
III. THE POST-ARTHREX CASES
The Supreme Court and appellate decisions in U.S. v. Arthrex impacted
over 100 pending appeals from the PTAB from late 2019 through mid-2021.
This Article first discusses how the Federal Circuit handled those postArthrex cases after the Supreme Court decision, with a focus on how the
parties in those cases wished to proceed. This Article then provides some
perspectives on Arthrex and how it will shape PTAB practice in the future.
A. The Federal Circuit Asked Parties How They Want to Proceed
Rather than pronounce a new procedure after the Supreme Court
vacated its ruling, the Federal Circuit polled the parties about how they
wished their appeals to proceed under the new regime. Two days after the
Supreme Court released its decision in Arthrex, the Federal Circuit released
an order in cases that were potentially affected by the Arthrex decision that
stated:
(1) Within 14 days from the date of this order, the parties that raised
an Appointments Clause challenge shall file a brief, not to exceed 10 pages
double-spaced, explaining how they believe their cases should proceed in
light of Arthrex. Responses from the other parties, including the United
States Patent and Trademark Office, subject to the same length
restrictions, are due within 14 days thereafter.
(2) All deadlines and proceedings are stayed.14

This order, in effect, allowed the appellants and appellees that had
pending appeals with live Arthrex challenges the opportunity to “explain[]
how they believe their cases should proceed” and gave other parties,
including the USPTO, a chance to respond.15

https://www.commerce.gov/about/leadership/drew-hirshfeld (last visited September 13, 2021)
[https://perma.cc/A4EV-RR4R]; Dani Kass, Patent Commissioner Takes Over As Temporary USPTO
Head, LAW360 (Jan. 20, 2021 12:47 PM EST), https://www.law360.com/articles/1346777/patentcommissioner-takes-over-as-temporary-uspto-head [https://perma.cc/A2SS-9JSF].
14. See, e.g., Order, Arthrex at 1, Uniloc 2017 LLC v. Google LLC, No. 19-2137 (Fed. Cir. June
23, 2021), ECF No. 60.
15. Id.
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B. Most Patent Owners Dropped Their Constitutional Challenges
In their briefs responding to the Federal Circuit’s order, the majority of
patent owner appellants dropped their Appointments Clause challenges and
asked the Federal Circuit to move on to the merits. Even then, however,
there was a spectrum of strategical responses. Most appellants explicitly
waived their Arthrex challenge.16 But other appellants simply said nothing
about whether or not they were waiving their Arthrex challenge.17 Still
others stated that they were withdrawing the Arthrex challenge, but were not
explicitly waiving it.18
As always, there were outliers. One appellant asked the Federal Circuit
to reverse on the merits, but simultaneously suggested that if the Federal
Circuit affirmed the merits, then the Federal Circuit should remand to the
director for further review.19 In Teva Pharmaceuticals v. Eli Lilly, the
USPTO responded to appellant Teva that a limited remand would be proper
but that Teva and other appellants should not be able to use the Appointments
Clause as a backup—that the case should be remanded immediately or not
at all.20
Other appellants within the merits group apparently felt they were too
deep into their case, and stated that since the appeal was advanced, it would
be best for the Federal Circuit to decide the appeal instead of remanding for
director review.21
C. Some Patent Owners Opted for Remand to the USPTO
However, a minority of appellants saw the Arthrex decision as
vindicating their challenges and asked the Federal Circuit to remand to the
director. But also within this group, there were interesting wrinkles in how
different appellants wanted the remand to proceed. About half of the
appellants requesting remand also challenged the acting director Drew
Hirshfeld’s authority to perform reviews of the final decisions made by the
administrative law judge as a director or acting director of the USPTO.22 The
16. See e.g., Appellant Uniloc 2017 LLC’s Statement in Response to the Court’s June 23, 2021
Order Regarding Arthrex at 1, Uniloc 2017 LLC v. Google LLC, No. 19-2137 (Fed. Cir. Jul. 7, 2021),
ECF No. 61.
17. See e.g., Brief of Appellant Qualcomm Incorporated in Response to the Court’s June 23, 2021
Order at 2-3, Qualcomm Inc. v. Apple Inc., No. 20-1558 (Fed. Cir. Jul. 7, 2021) ECF No. 57.
18. See e.g., Brief Regarding Withdrawal of Appointments Clause Challenge of Appellant Magseis
FF LLC at 2, Magseis FF LLC v. Seabed Geosolutions (US) Inc., No. 20-1346 (Fed Cir. July 7, 2021),
ECF No. 65.
19. See Appellant’s Supplemental Brief at 9, Teva Pharms. v. Eli Lilly & Co., No. 20-1747 (Fed.
Cir. Jul. 7, 2021), ECF No. 73.
20. See Intervenor’s Response in Connection with the Court’s Omnibus Arthrex Briefing Order at
3-4, Teva Pharms. v. Eli Lilly & Co., No. 20-1747 (Fed. Cir. Jul. 21, 2021), ECF No. 75.
21. See Appellant the Chemours Company FC, LLC’s Brief Regarding Arthrex Decision at 1,
Chemours Co. FC, LLC v. Daikin Indus., Ltd., No. 20-1289 (Fed. Cir. Jul. 2, 2021), ECF No. 66.
22. See e.g., Appellant’s Response to Post-Anthrex Briefing Order at 3, Corephotonics, Ltd. v.
Apple Inc., No. 20-1424 (Fed. Cir. Jul. 7, 2021), ECF No. 64.
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appellants in these cases argued that acting director Hirshfeld was neither
Presidentially-appointed nor Senate-confirmed, and therefore not a properly
appointed principal officer with the ability to issue a final binding decision.23
Instead, these appellants argued that Hirshfeld is simply acting as director
until the current administration appoints a more permanent director, who
would still need to be confirmed by the Senate.24 According to some
appellants, acting director Hirshfeld—like pre-Arthrex APJs—was not
properly appointed and therefore would be considered an inferior officer who
would be unable to review the decisions of the APJs in the way the
Constitution required.25 The appellants in these cases, however, still wanted
a remand to argue this point to the USPTO (and presumably to the Federal
Circuit if and when the USPTO disagreed with them).26
Alternatively, most of the other appellants who requested remand
seemed content with remand under the “interim Director review process”
provided on the USPTO’s website.27 Some appellants explicitly requested
that Hirshfeld follow the Administrative Procedure Act when using his
discretion for the review.28 These appellants wanted to ensure that the
director’s decisions on whether to rehear an AIA decision, which they argued
is a formal adjudication under the Administrative Procedure Act, satisfied
the standards under the Administrative Procedure Act, including sufficient
explanation to ensure that the decisions are not arbitrary and capricious.29
The appellants who wanted a remand had some outliers as well. A small
group simply wanted the Federal Circuit to vacate on the merits under
Arthrex.30 The appellants in these cases argued that since the acting director
was not confirmed by the Senate, the only proper remedy available was to
vacate the final written decision rather than remand for potential rehearing
by an inferior officer. To date, however, the Federal Circuit has declined all
such requests.

23. Id.
24. Kass, supra note 13.
25. See e.g., Brief for Appellant Cupp Computing AS, at 2-4, CUPP Computing AS v. Trend Micro
Inc. at 3, No. 20-2059 (Fed. Cir. Jul. 7, 2021), ECF No. 45.
26. Rovi’s Brief in Response to Court’s June 23 Order Concerning United States V. Arthrex, at 3,
Rovi Guides, Inc. v. Hirshfeld, No. 20-2288 (Fed. Cir. Jul. 2, 2021), ECF No. 40.
27. See e.g., Appellant True Spec Golf LLC’s Brief in Light of the Supreme Court’s Arthrex
Decision at 4, True Spec Golf LLC v. Club Champion LLC, No. 21-1612 (Fed. Cir. Jul. 7, 2021), ECF
No. 15.
28. See Brief of Appellant Cellspin Soft, Inc. Regarding how This Case Should Proceed in Light of
Anthrex at 4-5, Cellspin Soft, Inc. v. Canon U.S.A., Inc., No. 20-1947 (Fed. Cir. Jul. 7, 2021), ECF No.
70.
29. Id.
30. See e.g., Brief for Appellant Cupp Computing AS, at 4, CUPP Computing AS v. Trend Micro
Inc., No. 20-2059 (Fed. Cir. Jul. 7, 2021), ECF No. 45.
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D. Responses from Petitioners and the USPTO Were Mixed
As mentioned above, under the Federal Circuit’s Order, after the
appellants submitted what relief they wanted in these cases, appellees and
other parties had 14 days to respond.31
How appellees and the USPTO responded depended, in large part, on
what the appellant patent owner requested the Federal Circuit to do. In cases
when the Arthrex challenger wanted to move on the merits, appellees and the
USPTO largely agreed and said they considered the Arthrex challenge
waived as a result.32 Additionally, in some cases where appellants wanted
to move on the merits, and appellees did not respond, the USPTO filed a
reply saying that the appellant waived the Arthrex challenge by agreeing to
move on the merits, and therefore the decision did not affect the USPTO.33
However, in some other cases where the appellant wanted to move on the
merits and the appellee did not respond, the USPTO declined to intervene.34
In still other cases where the appellee did not respond, the Federal Circuit
lifted the stay and oral arguments were scheduled.35
Responses were more varied when the Arthrex challenger asked for
remand to the USPTO. In most cases, the appellees and USPTO agreed that
limited remand was appropriate.36 In at least some of these instances where
appellant asked for a remand, the appellee opposed any appellant request to
vacate the final written decision, while stating that the remand should be
congruent with the limited remand that was authorized by the Supreme Court
in Arthrex.37 The appellees in these cases argued that in Arthrex, the
Supreme Court held that Arthrex was not entitled to a hearing before a new
panel of APJs, and the Supreme Court rejected Arthrex’s argument that it
was entitled to a dismissal. Accordingly, these appellees stated that it defied
logic for appellants to suggest that they could receive a remedy that is greater
than the one the Supreme Court gave Arthrex, or to receive a remedy that the
Supreme Court explicitly rejected in Arthrex.38
31. See e.g., Order, Chemours Co. FC, LLC v. Daikin Indus., Ltd. No. 20-1289 (Fed. Cir. June 23,
2021), ECF No. 65.
32. See e.g., Apple Inc’s Response to the Court’s Order Regarding Appointments Clause
Challenges, at 1, Omni MedSci, Inc. v. Apple Inc., No. 21-1229 (Fed. Cir. Jul. 20. 2021), ECF No. 48.
See discussion infra Part III.e.
33. See e.g., Intervenor’s Response in Connection with the Court’s Omnibus Arthrex Briefing
Order, at 1, Quest Diagnostics Inv. V. Lab’y Co., No. 21-1115 (Fed. Cir. Jul. 21, 2021), ECF No. 31. See
discussion infra Part III.e.
34. See e.g., IPA Techs. Inc. v. Google LLC, No. 21-1438 (Fed. Cir.).
35. See e.g., Order, Uniloc 2017 LLC v. Google LLC., No. 19-2277 (Fed. Cir. Jul. 12, 2021), ECF
No. 62.
36. See e.g., Intervenor’s Response in Connection with the Court’s Omnibus Arthrex Briefing
Order, at 1, Cellspin Soft, Inc. v. Canon U.S.A., Inc., No. 20-1247 (Fed. Cir. Jul. 21, 2021), ECF No. 71;
Brief for Appellees Regarding How This Appeal Should Proceed in View of Arthrex at 2-3, Cellspin Soft,
Inc. v. Canon U.S.A., Inc., No. 20-1947 (Fed. Cir. Jul. 21, 2021), ECF No. 72.
37. See e.g., Response of Appellee Trend Micro Inc. Pursuant to Court’s June 23, 2021 Order, at 4,
CUPP Computing AS v. Trend Micro Inc., No. 20-2059 (Jul. 21, 2021), ECF No. 47.
38. Id. at 3.
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Some appellees, however, did not agree to remand. These appellees
argued that the appellant waived the challenge in Arthrex because the
appellant did not raise the issue before the Board, either in an appellate
motion or by other similar means. Because the appellants did not raise the
Arthrex challenge previously, the appellees considered it waived.39
In cases where the appellant questioned acting director Hirshfeld’s
appointment status, the USPTO demurred.40 Interestingly, one appellee
noted that the USPTO is already a party to the appeal and suggested that the
USPTO could simply brief its position about the remand, thereby sparing the
Federal Circuit and the parties of what looked to be an avoidable remand
cycle. Still other Appellees did not explicitly take a position on the
appellant’s request for a remand.41
E. Federal Circuit Largely Sided with Appellants’ Wishes
The Federal Circuit largely took one of two paths in responding to the
parties’ briefs. The first path was relatively straightforward because the
parties agreed to proceed to the merits without pressing the constitutional
challenges further. In the majority of those cases, the Federal Circuit issued
orders lifting a stay and moving forward with the proceedings.42
The second path was less straightforward because the parties had
conflicting positions about whether and how remand should proceed. In
some cases where appellants sought remand, the appellees insisted that the
Arthrex challenge was waived because the appellant did not raise the
challenge early enough before the Board, in an appellate motion, or other
similar means.43 In these “waiver” cases, the Federal Circuit remanded for
the “limited purpose of allowing appellant the opportunity to request
Director rehearing of the final written decision,” but warned that the
“[a]ppellant must file the requests for rehearing within 30 days from the date
of this order.” The Federal Circuit retained appellate jurisdiction and
instructed, “[a]ppellant shall inform this court within 14 days of any decision
denying rehearing.” Id. As for the USPTO, the orders stated that “[w]ithin
14 days of a decision granting rehearing, intervener shall inform the court of
that decision and make any request to remand the case(s) in full or continue
39. See e.g., Brief for Appellees in Response to the Court’s June 23, 2021 Order at 2, VirnetX Inc.
v. Mangrove Partners Master Fund, No. 20-2271 (Fed. Cir. Jul. 21, 2021), ECF No. 49. Whether the
Federal Circuit actually considered the Arthrex challenged waived is discussed infra at II.E
40. See e.g., Interveners Response in Connection with the Court’s Omnibus Arthrex Briefing Order
at 3, Rovi Guides, Inc. v. Hirshfeld, No. 20-2206 (Fed. Cir. Jul. 21, 2021), ECF No. 50.
41. See, e.g., Cross-Appellant’s Brief in Response to the Court’s June 23, 2021 Order, UUSI, LLC
v. Samsung Elecs. Co., No. 21-1060 (Fed. Cir. Jul. 21, 2021), ECF No. 35.
42. See, e.g., Order, Intuitive Surgical Operations, Inc. v. Auris Health, Inc., No. 21-1473 (Fed. Cir.
Aug. 13, 2021), ECF No. 25.
43. See, e.g., Appellee’s Brief Re: Arthrex at 4, MobilePay LLC v. Unified Patents, No. 20-2102
(Fed. Cir. Jul. 20, 2021), ECF No. 49.
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the stay of proceedings. The intervener’s request shall include a statement of
consent or opposition.”44 The vast majority of the cases where appellant
asked for a remand, and the appellee disagreed, resulted in a similar if not
identical order.45
In short, the Federal Circuit largely did what appellants wanted it to do.
When the appellant wanted a remand, in most cases the Federal Circuit
agreed, regardless of what the appellee said. When the appellant wanted to
move on the merits, the Federal Circuit lifted a stay and proceeded without
explicitly addressing whether the Arthrex challenge was waived. The Federal
Circuit could have also ordered this way on remand, if for no other reason
than consistency. Either way, cases where the Federal Circuit ordered a
limited remand are interesting because but for the Supreme Court’s decision
in Arthrex, these appellants likely would have never requested it.
IV. THE LONG-TERM IMPACT OF ARTHREX
Generally, the Arthrex decision may not cause too much upheaval
beyond a hundred or so appeals. Once there is a Presidentially-appointed and
Senate-confirmed director, that director will clearly be able to review APJs’
final written decisions by exercising his or her discretion. There is currently
no requirement that the director rehear any cases, so the interim director
review will likely remain discretionary for the foreseeable future.
Whether it makes sense to seek director review or rehearing remains to
be seen. Currently—Arthrex aside—rehearing requests typically fail at the
PTAB. For reference, the PTAB grants rehearing under 15% of the time. 46
It seems unlikely that these rates will change because of Arthrex, even
though now these requests will be aimed at the director. The USPTO has
stated in a post Arthrex Q&A that requests for director review will be
evaluated by an advisory committee established by the director; however,
the membership and size of this committee have not yet been specified. The
advisory committee may look to, for example, material issues of fact or law
that the Board misapprehended or overlooked; novel issues of law or policy;
issues on which Board panel decisions are split; issues of particular
importance to the Office or patent community; or inconsistencies with Office
procedures, guidance, or decisions. Additionally, an internal management
team will also review final written decisions using the same criteria as used
by the advisory committee to determine whether the director should review

44. See, e.g., Order, SIPCO, LLC v. Emerson Elec. Co., No. 21-1039 (Fed. Cir. Aug. 2, 2021), ECF
No. 34.
45. See, e.g., id.
46. Scott McBride & Alex Vogler, Supreme Court Decision Drives the PTAB’s Future,
IPWatchdog, (June 23, 2021), https://www.ipwatchdog.com/2021/06/23/arthrex-aftermath-landmarksupreme-court-decision-drives-ptabs-future/id=134930/ [https://perma.cc/AG62-ER9N].
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a decision sua sponte.47 It is still too early, however, to evaluate how often
the advisory committee or the internal management team will grant reviews.
What’s more, the director will likely rehear only final written decisions, as
opposed to institution decisions or decisions on matters like motions to
amend or motions for additional discovery. So even though petitioners and
respondents now have a procedure to have final written decisions reviewed
by the director, that does not mean such a review will be likely.
Another potential hurdle is that petitioners and patent owners in PTAB
proceedings may continue to challenge acting director Hirshfeld’s status
since he was neither appointed by the President nor confirmed by the Senate.
The frequency and results of these challenges remain to be seen.
V. CONCLUSION
While Arthrex disrupted the progress of over 100 PTAB appeals, most
of the post-Arthrex cases are now resolved. Once there is a Presidentiallyappointed and Senate-confirmed director, there should be no Arthrex-related
challenges and the director can use his or her discretion to review decisions
made by PTAB APJs. However, such cases may not be reheard with a
frequency that petitioners and respondents would like, and in all events,
dissatisfied parties will likely find themselves right back where they started
before the first Arthrex challenge: Presenting their complaints on appeal to
the Federal Circuit.

47. Arthrex
Q&As,
USPTO,
https://www.uspto.gov/patents/patent-trial-and-appealboard/procedures/arthrex-qas (last visited September 28, 2021) [https://perma.cc/BL56-9J8B].

